Showing 8351-8360 of 9737 results for "".
- Vyome Biosciences Announces FDA Acceptance of Investigational New Drug Application for VB-1953 to Treat Acnehttps://practicaldermatology.com/news/vyome-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-vb-1953-to-treat-acne/2458766/The FDA accepted Vyome Biosciences’ Investigational New Drug (IND) Application for the initiation of clinical studies for VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon. “Today m
- Brickell Biotech Achieves Positive Phase 2b Results for BBI-4000 for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-achieves-postive-phase-2b-results-for-bbi-4000-for-hyperhidrosis/2458772/Brickell Biotech, Inc. shared the results of its Phase 2b study of BBI-4000 (sofpironium bromide) for the topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The multicenter, randomized, double blind, vehicle-controlled Phase 2b study was designed to evaluate the
- Practical Dermatology Preview: Drug Companies, Insurance Companies, Pharmacists, the Government, Doctors and…Oh, Patients!https://practicaldermatology.com/news/practical-dermatology-preview-drug-companies-insurance-companies-pharmacists-the-government-doctors-andoh-patients/2458774/Recently, a relationship between Valeant Pharmaceuticals and a specialty pharmacy, Philidor, was revealed, with significant consequences to Valeant and equally significant consequences for the pharmacy. The full story is still unfolding as of this time, but the interpretations of these type
- Valeant Issues Updated Financial Guidancehttps://practicaldermatology.com/news/valeant-issues-updated-financial-guidance/2458779/Valeant Pharmaceuticals International, Inc. announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016. "We are very excited about the strong future given our broad portfolio of brands, our upcoming launch products and ou
- ASDS Goes Triple Platinum in MarCom Awardshttps://practicaldermatology.com/news/asds-goes-triple-platinum-in-marcom-awards/2458778/The American Society for Dermatologic Surgery and American Society for Dermatologic Surgery Association were recognized with 14 awards – including three Platinums – in the 2015 MarCom Awards competition. The MarCom Awards is an international competition administered and judged by the
- Valeant Enters Fulfillment Agreements With Walgreenshttps://practicaldermatology.com/news/valeant-enters-fulfillment-agreements-with-walgreens/2458783/Valeant Pharmaceuticals International, Inc. entered into new fulfillment agreements with Walgreens and indicated that it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant says it will reduce
- Valeant Offers Comment on Fake Twitter Accounthttps://practicaldermatology.com/news/valeant-offers-comment-on-fake-twitter-account/2458786/Valeant issued the following statement about a fake Twitter account created to impersonate Mike Pearson: We are aware that someone impersonating Mike Pearson has created an account on Twitter, and we have contacted Twitter to report the unauthorized use. Mike Pearson does not
- AMA Disappointed CMS Moving Ahead with Problematic Information on Website for Patientshttps://practicaldermatology.com/news/ama-disappointed-cms-moving-ahead-with-problematic-information-on-website-for-patients/2458788/The AMA is "dismayed" that CMS is moving forward with its Physician Compare website, the AMA has issued a statement to express its concern "that incomplete and potentially inaccurate information...will misinform patients." “Given the widespread accuracy issu
- Rock Creek Pharmaceuticals Adds KOLs to Enhance Dermatological Disease Programhttps://practicaldermatology.com/news/rock-creek-pharmaceuticals-adds-kols-to-enhance-dermatological-disease-program/2458794/Rock Creek Pharmaceuticals, Inc., a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, has retained two Key Opinion Leaders (KOLs), each having renowned international expertise in dermatological d
- DermTech Announces New Websitehttps://practicaldermatology.com/news/dermtech-announces-new-website/2458796/DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced the release of its new website (www.dermtech.com), designed to provide education and inf